Vanda Pharmaceuticals Inc.
VNDAVanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of proprietary drugs to treat central nervous system disorders, including schizophrenia, bipolar disorder, and other mental health conditions. The company is known for its innovative therapies and has a portfolio that includes products addressing underserved patient populations. Founded in 2000 and headquartered in Washington, D.C., Vanda emphasizes research and development to bring new treatment options to market.
Company News
U.S. stock futures declined on New Year's Eve as hopes for a year-end Santa Claus rally fade. Markets remain jittery following President Trump's threats against Federal Reserve Chair Jerome Powell. Investors await the Initial Jobless Claims report before market open. The S&P 500, Dow Jones, and Nasdaq 100 all traded lower in premarket, with sever...
The gastroparesis market is expected to grow significantly at a 21.9% CAGR by 2034, driven by novel therapeutic approaches targeting different receptor mechanisms and addressing current treatment limitations.
Vanda Pharmaceuticals reported a Q2 2025 net loss of $27.2 million, with revenue rising 4% to $52.6 million. Fanapt® showed strong sales growth, while HETLIOZ® and PONVORY® experienced declines. The company continues to invest in its product pipeline and expand market reach.
The schizophrenia market is growing due to increased R&D activities, advancements in neurobiology and biomarkers, and ongoing clinical trials for more effective treatments. This has attracted significant investments and led to the development of innovative therapies, including novel antipsychotics and personalized medicine.
Vanda (VNDA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
